Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyQualChoice Voyxact (IgAN) Coverage Update | OpenPa…
    Ask Trek AI about this page
    CurrentQualChoicePolicy CP.PHAR.775

    Sibeprenlimab-szsi (Voyxact) for IgA Nephropathy

    Customize your policy alerts

    Sign up for QualChoice Policy CP.PHAR.775 alerts

    Get alerted when Policy CP.PHAR.775 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governing prior authorization, medical necessity criteria, and coverage for Voyxact (sibeprenlimab-szsi) to reduce proteinuria in adults with primary IgA nephropathy for members of QualChoice lines of business.

    Policy Summary
    PayerQualChoice
    PolicySibeprenlimab-szsi (Voyxact) for IgA Nephropathy
    Policy CodePolicy CP.PHAR.775
    Change TypeNo material change
    Effective DateJun 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation (office notes, lab results) demonstrating the member meets all approval criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    400 mgdose / month (SC)
    ≥1 g/dayproteinuria threshold
    ≥30min eGFR
    6 moinitial auth
    6–12 mo

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    continued auth
    ©2026copyright

    Coverage Criteria for Voyxact (sibeprenlimab-szsi)

    Initial Therapy — Immunoglobulin A Nephropathy

    Covered when ALL of the following are met:

    Initial IgAN requirements: 1. Diagnosis of IgA nephropathy (IgAN) confirmed by kidney biopsy; 2. Prescribed by or in consultation with a nephrologist; 3. Age ≥ 18 years; 4. Documentation of both: (a) proteinuria ≥ 1 g/day or UPCR ≥ 0.75 g/g; (b) eGFR ≥ 30 mL/min/1.73 m2; 5. Member meets both, unless contraindicated or clinically significant adverse effects: (a) failure of a RAAS inhibitor for at least 12 weeks; (b) RAAS inhibitor dose ≥ 50% of maximum labeled dose; 6. Failure of an SGLT2 inhibitor at up to maximally indicated doses unless contraindicated or clinically significant adverse effects; 7. Failure of Filspari or Vanrafia at up to maximally indicated doses unless contraindicated or clinically significant adverse effects; 8. Requested dose does not exceed both: (a) 400 mg every 4 weeks; (b) 1 prefilled syringe per 4 weeks.

    Illinois HIM requests exempt from step therapy requirements per IL HB 5395

    Continuation Therapy

    Continued therapy covered when ALL of the following are met:

    Continued IgAN therapy requirements: 1. Member meets one of the following: (a) currently receiving medication via Centene benefit or previously met initial approval criteria; or (b) currently receiving medication and enrolled in a state/product with continuity-of-care regulations; 2. Member is responding positively to therapy as evidenced by: (a) decrease in UPCR from baseline; or (b) reduction in total urine protein per day from baseline; 3. If request is for a dose increase, new dose does not exceed both: (a) 400 mg every 4 weeks; (b) 1 prefilled syringe per 4 weeks.

    Non‑FDA approved indications that are not specifically addressed in this policy are not authorized for coverage unless the requestor provides sufficient documentation of efficacy and safety in accordance with the applicable off‑label use policies (e.g., CP.CPA.09 for commercial, HIM.PA.154 for Health Insurance Marketplace, and CP.PMN.53 for Medicaid) or unless coverage is supported by the member's evidence of coverage documents.

    For Medicaid members, when a state Medicaid coverage provision conflicts with the coverage provisions in this clinical policy, the state Medicaid provision takes precedence. Refer to the applicable state Medicaid manual for any specific coverage rules that apply to this medication.

    Clinical Thresholds and Key Values

    Proteinuria threshold — key/value
    Proteinuria threshold≥ 1 g/day or urine protein-to-creatinine ratio (UPCR) ≥ 0.75 g/g
    ContextRequired for initial approval of Voyxact in IgA nephropathy (must be documented)
    Measurement optionsCan be documented as total urine protein/day or UPCR in g/g
    eGFR threshold — key/value
    eGFR thresholdEstimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m2
    ContextRequired for initial approval of Voyxact in IgA nephropathy (documented value)
    Abbreviation

    Provider Requirements, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization required — coverage only when criteria met

    Prior authorization is required for Voyxact; therapy is considered medically necessary only when the policy’s specified initial or continued therapy criteria are met (see coverage criteria for diagnosis, proteinuria/eGFR thresholds, prior therapy requirements, and dosing limits).

    • Therapy limits: 400 mg every 4 weeks and 1 prefilled syringe per 4 weeks.
    Note

    Policy guides prior authorization and coverage determinations

    This clinical policy is intended to guide medical necessity determinations and to assist in making coverage decisions and administering benefits; prior authorization requirements are governed by the Health Plan’s administrative procedures. It does not guarantee payment or alter plan terms.

    Background on Voyxact and Indication

    Voyxact (sibeprenlimab‑szsi) is an APRIL blocker that received accelerated approval to reduce proteinuria in adults with primary immunoglobulin A nephropathy who are at risk for disease progression. Continued approval is contingent upon confirmatory trials because the long‑term effect on kidney function has not yet been established. Treatment and coverage decisions must follow the criteria in this policy, including specified proteinuria and renal function thresholds, and documentation requirements for efficacy and safety.

    Definitions and Abbreviations

    eGFR definition — estimated glomerular filtration rate
    DefinitionEstimated glomerular filtration rate (eGFR) — a measure of kidney function expressed in mL/min/1.73 m2
    Use in policyeGFR is used as an eligibility threshold for initial therapy
    Abbreviation sourceListed in Appendix A: Abbreviation/Acronym Key
    UPCR definition — urine protein-to-creatinine ratio
    DefinitionUPCR — urine protein-to-creatinine ratio; used to quantify proteinuria (expressed in g/g)
    Policy threshold exampleUPCR ≥ 0.75 g/g meets the proteinuria criterion for initial approval
    Policy Summary
    PayerQualChoice
    PolicySibeprenlimab-szsi (Voyxact) for IgA Nephropathy
    Policy CodePolicy CP.PHAR.775
    Change TypeNo material change
    Effective DateJun 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation (office notes, lab results) demonstrating the member meets all approval criteria.
    SourceLink
    On This Page
    Coverage Criteria for Voyxact (sibeprenlimab-szsi)Clinical Thresholds and Key ValuesProvider Requirements, Prior Authorization, and DocumentationBackground on Voyxact and IndicationDefinitions and Abbreviations
    eGFR = estimated glomerular filtration rate
    Step Therapy

    Step therapy — required prior medication failures

    Voyxact requests must document prior failure of a RAAS inhibitor for at least 12 weeks at a RAAS dose of ≥50% of the maximum labeled dose (unless contraindicated) and failure of an SGLT2 inhibitor at up to maximally indicated dosing; additionally, failure of Filspari or Vanrafia at up to maximally indicated doses is required unless contraindicated.

    • RAAS failure: ≥12 weeks and RAAS dose ≥50% of max labeled dose.
    • SGLT2 inhibitor failure: up to maximally indicated doses.
    • Also requires failure of Filspari or Vanrafia at up to maximally indicated doses, unless contraindicated.
    Note

    Step therapy note — no other step therapy requirements

    No additional or alternative step therapy requirements are specified elsewhere in this policy segment beyond those listed for initial approval; Illinois HIM requests are exempt per IL HB 5395 where noted in the criteria.

    • Illinois HIM exemption for step therapy effective 1/1/2026 (IL HB 5395).
    Documentation Required

    Required documentation — submit clinical records and labs

    Providers must submit supporting clinical documentation with the prior authorization request, such as office chart notes, laboratory results (e.g., UPCR, urine protein/day, eGFR), and other clinical information demonstrating that all approval criteria are met.

    • Documentation should include biopsy-confirmed IgAN, nephrology consult/prescriber, age, proteinuria and eGFR values, prior medication trial details (duration and dosing), and response measures for continuation requests (e.g., reduction in UPCR or urine protein).
    Billing Rule

    Submission must follow Health Plan administrative and legal requirements

    When submitting requests, providers must follow applicable Health Plan-level administrative policies and procedures and comply with state and federal legal and regulatory requirements; the Health Plan’s effective dates and regulatory obligations take precedence where applicable.

    Denial Risk

    Insufficient documentation or non‑FDA indications may lead to denial or request for more information

    Requests that lack the required supporting documentation or that request coverage for non‑FDA indications without sufficient evidence per off‑label policies may be denied; submissions that conflict with plan terms, exclusions, or state/federal requirements may also be denied or require additional information.

    • Incomplete documentation demonstrating criteria (e.g., biopsy, proteinuria, eGFR, prior therapy trials) may result in denial.
    • Non‑FDA indications require sufficient evidence per off‑label use policies (CP.CPA.09, HIM.PA.154, CP.PMN.53) or evidence of coverage documents.
    Note

    Coverage subject to plan documents, exclusions, and legal requirements

    Coverage and administration of benefits are subject to the terms, conditions, exclusions, and limitations of the member’s coverage documents and applicable state and federal requirements; a favorable medical necessity determination does not override plan contract language.

    Appendix reference
    UPCR listed in Appendix B abbreviation/key
    RAAS definition — renin-angiotensin-aldosterone system
    DefinitionRAAS — renin-angiotensin-aldosterone system
    Clinical roleRAAS inhibitors (e.g., irbesartan, losartan, lisinopril, benazepril) are required step therapy prior to Voyxact unless contraindicated
    Appendix referenceRAAS abbreviation listed in Appendix B
    APRIL blocker definition — mechanism of Voyxact (A Proliferation Inducing Ligand blocker)
    MechanismAPRIL blocker — agent that blocks A Proliferation Inducing Ligand (APRIL)
    Drug exampleSibeprenlimab-szsi (Voyxact) is an APRIL blocker
    Therapeutic intentUsed to reduce proteinuria in adults with primary IgA nephropathy under accelerated approval
    Health Plan definition
    Definition'Health Plan' means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates, as applicable.
    Policy applicationCoverage decisions and administration of benefits are subject to the Health Plan's terms, conditions, exclusions, and limitations
    DisclaimerThis clinical policy is a guide to medical necessity and does not constitute a contract or guarantee of payment